Table 2.

Peptides identified from HBV-derived antigens.

				Donor samples∗
Antigen	Position	Sequence†	HLA type‡	TF	HCC	HBV§	Viral load (IU/ml)	IEDB¶	PRM∗∗
HBsAg	6–17	STSNPLGFFPDH	NB	20		C	5.87E4/P		N
HBsAg	14–23H	FPDHQLHPAF	B∗08:01; B∗35:02; C∗04:01		22	AC	1.12E5/P		VG
HBsAg	14–23D	FPDHQLDPAF	B∗35:02; C∗04:01		22	AC	1.12E5/P		VG (2)
HBsAg	183–191	FLLTRILTI	B∗08:01; C∗04:01; C∗07:01		22	AC	1.12E5/P	◊	VG (3)
HBsAg	313–321	IPIPSSWAF	B∗08:01 B∗35:02; C∗04:01		22	AC	1.12E5/P	○●	N/A
HBsAg	256–264	RGPNLYSTL	A∗24:02 C∗07:02 C∗15:05	7		C	<2.0E1/N		N/A
Pol	11–21	LLLLDDDAGPV	A∗02:01		18	R	<2.0E1/N		N/A
Pol	705–714	RGTFVSPLPI	B∗57:01		18	R	<2.0E1/N		N/A

DDA, data-dependent acquisition; IEDB, Immune Epitope Database; IFNγ, interferon γ; Pol, polymerase; PRM, parallel reaction monitoring; TF, tumour-free.

^∗Donor tissue in which the corresponding peptide is identified.

^†Underscored amino acids are not in consensus with the NC_003977.2 reference sequence.

^‡NB: not predicted to bind donor HLA.

^§HBV status of patients in which peptides are identified: AC: acute-on-chronic infection; C: chronic infection; R: resolved infection.

^¶Whether a sequence is reported as HLA ligand in the IEDB or not. For reported sequences, it is indicated whether they are identified in a new context of HLA supertypes they were not previously associated with (◊) or in the context of both the described and another HLA supertype (○●). Peptides in bold are listed as immunogenic in the IEDB (i.e. positive multimer binding and/or IFNγ production).

^∗∗VG: Peptides with a very good match in the same sample as the DDA identification. The number of very good matches in additional samples is indicated between brackets (Supplementary Materials & methods; Table S5). N: not detected with PRM. N/A: peptides not included in the target list for PRM analyses.